fm8k-0509.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): April 23,
2009
(Exact
Name of Registrant as Specified in Its Charter)
(State or
Other Jurisdiction of Incorporation)
|
000-53404
|
87-0652870
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
|
|
|
3293
Harrison Blvd., Ste. 230, Ogden, UT
|
84403
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2.
below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 8.01 Other
Events
On April 23, 2009,
Bio-Path Holdings, Inc. (“Bio-Path”), announced that it had entered into
an agreement with ACORN CRO, a full service, oncology-focused clinical research
organization (CRO), to provide Bio-Path with a contract medical officer and
potentially other clinical trial support services. Concurrent with
signing the agreement, Bradley G. Somer, M.D., will serve as Bio-Path’s Medical
Officer and medical liaison for the conduct of the Company’s upcoming Phase I
clinical study of liposomal Grb-2 in refractory or relapsed Acute Myeloid
Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia
(ALL) and Myelodysplastic Syndrome (MDS).
The press release relating to this
announcement is attached hereto as an exhibit and is incorporated by reference
herein.
In accordance with General
Instruction B.2 of Form 8-K, the information in this Report, including Exhibit
99.1 hereto, shall not be deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, and shall not be incorporated by
reference into any registration statement or other document filed under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.
Item 9.01 Financial
Statements and Exhibits
Exhibits
|
|
Exhibit
Number
|
Description
|
|
|
|
|
|
|
|
|
99.1
|
Press
Release
|
|
SIGNATURES
Pursuant to the requirements of the
Securities Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly authorized.
|
Dated: April
27, 2009
|
BIO-PATH
HOLDINGS INC.
|
|
|
|
|
|
By:
/s/
|
|
|
Peter
H. Nielsen , Chief Executive
Officer
|